NU576 Unit 3 Quiz Questions

Student Name

Purdue University Globle 

NU576 NP II – Primary Care of Women’s Health

Prof. Name

Date

Quiz Questions

Perimenopause, menopause, hormone therapy, infertility evaluation, and gynecologic health are essential topics in advanced nursing practice. Healthcare providers should understand that perimenopause commonly begins between 35 and 40 years of age, menopause is frequently associated with vasomotor and genitourinary symptoms, hormone therapy requires individualized risk assessment, and infertility workups involve targeted diagnostic testing. Recognizing these normal reproductive transitions and associated conditions supports timely diagnosis, patient education, and evidence-based treatment planning.

Understanding Perimenopause and Menopause

Perimenopause is the reproductive transition period preceding menopause, characterized by fluctuating ovarian hormone production and changes in menstrual patterns. While the timing varies among women, perimenopause often begins between the ages of 35 and 40 and may last several years before menopause is reached.

During this stage, ovulation becomes less predictable, but pregnancy remains possible. Therefore, women who do not desire pregnancy should continue using contraception until menopause is confirmed.

Common symptoms associated with perimenopause include:

• Hot flashes

• Night sweats

• Irregular menstrual cycles

• Increased cycle variability

• Mood changes

• Sleep disturbances

• Changes in ovulation patterns

Hot flashes remain one of the most prevalent symptoms, affecting approximately 60% to 80% of women during the menopausal transition.

Menopause Hormone Therapy

Hormone therapy (HT) is considered one of the most effective treatments for moderate to severe menopausal symptoms. Clinical decision-making should include a thorough evaluation of the patient’s age, medical history, symptom severity, and individual risk factors.

Benefits of Hormone Therapy

Hormone therapy may provide several benefits, including:

• Reduction of hot flashes and night sweats

• Preservation of bone density

• Improvement of genitourinary syndrome of menopause

• Enhanced quality of life in appropriately selected patients

Women with an intact uterus should receive a progestin in combination with estrogen therapy to reduce the risk of endometrial hyperplasia and endometrial cancer associated with unopposed estrogen exposure.

Contraindications to Hormone Therapy

Postmenopausal hormone therapy is not appropriate for all patients. Absolute or significant contraindications include:

• Unexplained vaginal bleeding

• History of estrogen-sensitive malignancies

• Active or prior thromboembolic disease, when clinically relevant

• Significant cardiovascular risk factors based on individual assessment

Patients with a history of deep vein thrombosis (DVT) or those who are poor candidates for hormone therapy should be evaluated for nonhormonal alternatives.

Nonhormonal Treatment Options for Menopausal Symptoms

Many women either prefer to avoid hormone therapy or have contraindications that limit its use. Several nonhormonal medications have demonstrated effectiveness in managing vasomotor symptoms.

Common alternatives include:

• Paroxetine

• Venlafaxine (Effexor)

• Sertraline (Zoloft)

• Gabapentin

Clonidine is generally considered less favorable because of its comparatively lower efficacy and increased potential for adverse effects.

Genitourinary Syndrome of Menopause

Genitourinary syndrome of menopause (GSM), previously referred to as atrophic vaginitis, results from declining estrogen levels after menopause. These hormonal changes affect the vulva, vagina, urethra, and surrounding tissues.

Clinical Findings Associated With Estrogen Deficiency

Patients commonly report:

• Vaginal dryness

• Vaginal irritation

• Dyspareunia

• Thinning of vaginal tissues

• Recurrent urinary symptoms

• Vaginal pH greater than 5

The vulva contains a high concentration of estrogen receptors, making it particularly susceptible to estrogen deficiency.

Role of Topical Estrogen Therapy

Low-dose vaginal estrogen is highly effective for localized menopausal symptoms and may:

• Improve vaginal lubrication

• Restore vaginal tissue integrity

• Reduce discomfort during intercourse

• Decrease the frequency of recurrent urinary tract infections

Women receiving systemic hormone therapy who continue to experience genitourinary symptoms may benefit from supplemental topical estrogen after appropriate clinical evaluation.

Osteoporosis Prevention and Management

Estrogen plays a critical role in maintaining bone health. Following menopause, declining estrogen levels significantly increase the risk of osteoporosis and fragility fractures.

Medications Used for Osteoporosis Prevention

Several medications are commonly prescribed for osteoporosis prevention and treatment:

• Alendronate (Fosamax): A bisphosphonate frequently administered once weekly to improve bone mineral density.

• Raloxifene: A selective estrogen receptor modulator (SERM) that supports bone health and may reduce the risk of invasive breast cancer in selected patients.

Lifestyle modifications, including adequate calcium intake, vitamin D supplementation, smoking cessation, and weight-bearing exercise, should also be incorporated into osteoporosis prevention strategies.

Amenorrhea: Definitions and Clinical Significance

Amenorrhea refers to the absence of menstrual periods and is classified as either primary or secondary.

Primary Amenorrhea

Primary amenorrhea is diagnosed when:

• Menarche has not occurred by age 15.

• Menstruation is absent by age 13 in the absence of secondary sexual characteristics.

Secondary Amenorrhea

Secondary amenorrhea is defined as:

• Absence of menstruation for more than three months in individuals with previously regular cycles.

• Absence of menstruation for six months in individuals with previously irregular cycles.

A comprehensive evaluation should include pregnancy testing, hormonal assessment, and investigation of potential endocrine or structural causes.

Dysmenorrhea Management

Dysmenorrhea is characterized by pelvic pain associated with menstruation and is among the most common gynecologic complaints in reproductive-age women.

Evidence-based management approaches include:

• Nonsteroidal anti-inflammatory drugs (NSAIDs)

• Regular physical activity

• Application of heat therapy, such as heating pads

• Lifestyle modifications and stress management techniques

Persistent or severe dysmenorrhea warrants further evaluation to rule out secondary causes such as endometriosis or pelvic inflammatory disease.

Infertility Evaluation and Diagnostic Testing

Infertility assessments focus on identifying ovulatory disorders, anatomic abnormalities, and other reproductive health concerns affecting conception.

Ovulation and Pelvic Assessment

Ultrasonography performed near ovulation can help evaluate:

• Follicular development

• Endometrial thickness

• Pelvic anatomy

• Structural abnormalities impacting fertility

Additional Diagnostic Procedures

A hysterosalpingogram (HSG) is typically scheduled two to five days after menstruation. This procedure evaluates:

• Uterine cavity shape

• Fallopian tube patency

• Structural abnormalities

Laparoscopy is often performed early in the menstrual cycle to assess pelvic anatomy and diagnose conditions such as endometriosis, adhesions, or other fertility-related disorders.

High-Yield NU576 Unit 3 Quiz Facts

The following concepts are frequently tested in NU576 Unit 3 assessments:

• Perimenopause commonly begins between ages 35 and 40.

• Hot flashes affect approximately 60% to 80% of women during menopause.

• Pregnancy remains possible during perimenopause.

• Ovulation becomes increasingly irregular during the menopausal transition.

• Testosterone levels are not typically elevated during menopause.

• Progestin is prescribed with estrogen therapy in women with an intact uterus.

• Menstruation gradually becomes irregular before cessation at menopause.

• Soy and red clover are examples of phytoestrogens.

• Estrogen deficiency contributes to elevated vaginal pH and atrophic changes.

• Osteoporosis risk increases substantially after menopause.

Clinical Takeaways for Advanced Practice Nurses

Advanced practice nurses should be prepared to educate patients about reproductive aging, assess menopausal symptoms, recommend appropriate treatment options, and recognize when further evaluation is needed. A comprehensive understanding of hormone therapy, osteoporosis prevention, menstrual disorders, and infertility diagnostics supports safe, patient-centered care across the lifespan.

References

American College of Obstetricians and Gynecologists. (2023). Hormone therapy for menopause. https://www.acog.org/womens-health/faqs/hormone-therapy-for-menopause

American Society for Reproductive Medicine. (2021). Evaluation and treatment of infertility. https://www.asrm.org/topics/topics-index/infertility/

National Institute on Aging. (2024). What is menopause? National Institutes of Health. https://www.nia.nih.gov/health/menopause

National Osteoporosis Foundation. (2023). Osteoporosis prevention and treatment. https://www.nof.org/

NU576 Unit 3 Quiz Questions

North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028